- Home
- GRND vs AKRO Comparison
GRND vs AKRO Comparison
Compare GRND & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- AKRO
- Stock Information
- Founded
- GRND 2009
- AKRO 2017
- Country
- GRND United States
- AKRO United States
- Employees
- GRND N/A
- AKRO N/A
- Industry
- GRND Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- AKRO Health Care
- Exchange
- GRND Nasdaq
- AKRO Nasdaq
- Market Cap
- GRND 2.1B
- AKRO 2.1B
- IPO Year
- GRND N/A
- AKRO 2019
- Fundamental
- Price
- GRND $13.65
- AKRO $31.59
- Analyst Decision
- GRND Strong Buy
- AKRO Strong Buy
- Analyst Count
- GRND 3
- AKRO 7
- Target Price
- GRND $15.33
- AKRO $43.20
- AVG Volume (30 Days)
- GRND 464.9K
- AKRO 441.5K
- Earning Date
- GRND 11-07-2024
- AKRO 11-11-2024
- Dividend Yield
- GRND N/A
- AKRO N/A
- EPS Growth
- GRND N/A
- AKRO N/A
- EPS
- GRND N/A
- AKRO N/A
- Revenue
- GRND $300,034,000.00
- AKRO N/A
- Revenue This Year
- GRND $30.64
- AKRO N/A
- Revenue Next Year
- GRND $21.70
- AKRO N/A
- P/E Ratio
- GRND N/A
- AKRO N/A
- Revenue Growth
- GRND 34.98
- AKRO N/A
- 52 Week Low
- GRND $5.71
- AKRO $11.36
- 52 Week High
- GRND $13.90
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- GRND 63.17
- AKRO 66.34
- Support Level
- GRND $13.06
- AKRO $29.34
- Resistance Level
- GRND $13.90
- AKRO $32.15
- Average True Range (ATR)
- GRND 0.42
- AKRO 1.26
- MACD
- GRND 0.06
- AKRO 0.10
- Stochastic Oscillator
- GRND 80.54
- AKRO 99.74
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.